The question eventually arises for every man on long-term TRT: at what age, if ever, does it make sense to stop? The answer involves balancing continued benefits against age-related risk evolution and individual health trajectory.
The Case for Continuing
- Bone protection becomes more important: Osteoporotic fracture risk increases dramatically with age. Testosterone (via estradiol conversion) is the primary hormonal protector of bone density in men. Stopping TRT in a 70-year-old removes bone protection at the age when it's most needed.
- Muscle preservation: Sarcopenia (age-related muscle loss) accelerates after 70. TRT helps maintain lean mass and functional strength, reducing fall risk and preserving independence.
- Cognitive function: While not definitively proven, testosterone may support cognitive function in aging men. Removing it during a period of increasing cognitive vulnerability is a reasonable concern.
- Quality of life: The mood, energy, and libido benefits of TRT don't become less valuable with age. If anything, maintaining vitality in older age is more impactful.
The Case for Reconsideration
- Cardiovascular risk evolution: While TRAVERSE showed no increased MACE with TRT in men 45–80, individual cardiovascular risk increases with age. Men who develop significant cardiovascular disease may benefit from individualized risk-benefit discussion.
- Hematocrit management: Polycythemia becomes harder to manage in older men, particularly those on anticoagulants or with other hematologic concerns.
- Medication burden: Some older men prefer to reduce their medication count. If TRT is the least impactful medication and stopping doesn't produce significant symptoms, simplification has value.
- Prostate management: Men diagnosed with prostate cancer face individualized TRT decisions. While TRT doesn't cause prostate cancer, management decisions for existing cancer may involve testosterone manipulation.
The Decision Framework
- Continue if: Good overall health, no contraindications, labs well-managed, subjective benefit maintained
- Reconsider if: Significant cardiovascular disease develops, hematocrit management becomes problematic, prostate cancer diagnosis, or patient prefers medication simplification
- Never stop abruptly: If discontinuing, taper with PCT support and monitor for symptomatic deterioration
The Bottom Line
No Magic Cutoff Age
There is no evidence-based age at which TRT should automatically stop. The decision to continue or discontinue is individualized based on health status, risk factors, symptom benefit, and patient preference. For healthy older men with well-managed labs and continued benefit, the argument for continuing TRT is as strong at 75 as it was at 55.